Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.

导出 OA

翻译打印收藏纠错

第一作者： Andrzej J,Jakubowiak

作者： Andrzej J,Jakubowiak ; Shaji,Kumar ; Rohan,Medhekar ; Huiling,Pei ; Patrick,Lefebvre ; Shuchita,Kaila ; Jianming,He ; Marie-Hélène,Lafeuille ; Annelore,Cortoos ; Anil,Londhe ; Panagiotis,Mavros ; Thomas S,Lin ; Saad Z,Usmani

关键词 cytogenetics daratumumab minimal residual disease multiple myeloma progression-free survival

主题词抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);多发性骨髓瘤(Multiple Myeloma);治疗结果(Treatment Outcome)

DOI 10.1093/oncolo/oyac067

PMID 35462406

发布时间 2024-08-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The oncologist

2022年27卷7期

e589-e596页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.

The oncologist

相似文献

The oncologist

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.

The oncologist

相似文献

The oncologist

相关期刊

检索历史清除